• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Darunavir for the treatment of HIV infection
【24h】

Darunavir for the treatment of HIV infection

机译：Darunavir用于治疗艾滋病毒感染

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Darunavir (DRV) was the last approved protease inhibitor (PI) and has been extensively used for the treatment of HIV in both na?ve and experienced subjects due to its high genetic barrier and efficacy. The introduction in clinical practice of integrase strand transfer inhibitors limited its role in the management of na?ve subjects and in antiretroviral treatment simplification strategies. However, recent data from trials that have investigated the new DRV/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) combination showed an excellent efficacy and tolerability of this coformulation both in na?ve patients and in those with viral suppression, making D/C/F/TAF a new option for the treatment of HIV infection. Areas covered: The authors present and discuss the efficacy and safety data of DRV when used in antiretroviral-na?ve, multiexperienced subjects and in the setting of treatment deintensification in subjects with viral suppression. Moreover, the authors evaluate the recent data from two different Phase III trials on D/C/F/TAF both in treatment-na?ve and virologically suppressed subjects. Expert opinion: Although novel antiretroviral drugs may become available over time, DRV continues to represent a valuable option for multiexperienced subjects and has a role in simplification regimens. In addition, the convenience of D/C/F/TAF coformulation may be useful for the future management of HIV-infected subjects.
机译：简介：Darunavir（DRV）是最后批准的蛋白酶抑制剂（PI），并且由于其高遗传障碍和功效而被广泛地用于治疗Na ve和经验的受试者。整合酶链转移抑制剂的临床实践引入限制了其在Naαve受试者和抗逆转录病毒治疗简化策略中的作用。然而，研究新的DRV / COBICISTAT / EMTRICTABINE / Tenofovir Alafenide（D / C / F / TAF）组合的试验中的近期数据显示了这种联合患者和病毒抑制的那些Coformulation的优异功效和耐受性，使D / C / F / TAF成为治疗HIV感染的新选择。所涵盖的区域：作者呈现并讨论DRV在抗逆转录病毒-NA'VE，多因素对象和病毒抑制中的治疗中的处理中的疗效和安全数据。此外，作者评估了在治疗 - Na ve和病毒抑制的对象中的两种不同期III试验中的近期D / C / F / TAF的数据。专家意见：虽然新型抗逆转录病毒药物可能随着时间的推移可以获得可用，但DRV继续代表多患科的有价值的选择，并在简化方案中具有作用。此外，D / C / F / TAF Coformulation的便利性对于艾滋病毒感染受试者的未来管理可能是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号